v3.25.3
Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€)
€ in Millions
6 Months Ended
Jun. 30, 2025
Jan. 01, 2025
Dec. 31, 2024
[3]
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]      
Beginning balance [1] € 641    
Payments made [1] (72)    
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [1],[2] 72    
Currency translation differences [1] (77)    
Ending balance [1] 564    
Current portion 0 [1],[3] € 72 € 72
Non-current portion 564 [1],[3] € 569 € 569
MSD contingent consideration (European Vaccines business)      
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]      
Beginning balance 72    
Payments made (72)    
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 1    
Currency translation differences (1)    
Ending balance 0    
Shire contingent consideration arising from acquisition of Translate Bio      
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]      
Beginning balance 568    
Payments made 0    
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 71    
Currency translation differences (76)    
Ending balance 563    
Other      
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]      
Beginning balance 1    
Payments made 0    
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 0    
Currency translation differences 0    
Ending balance € 1    
[1] As of January 1, 2025, this comprised a non-current portion of €569 million and a current portion of €72 million.
[2] Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.
[3] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.